Mildronate (Meldonium Dihydrate)

Meldonium blocks the enzyme γ‑butyrobetaine hydroxylase, decreasing the synthesis of carnitine. Lower carnitine levels shift cellular energy production from fatty‑acid oxidation toward glucose oxidation, a pathway that uses less oxygen per ATP molecule. This improves the efficiency of heart and skeletal‑muscle cells during periods of limited blood flow.

The exact dose of Mildronate is individualized by the prescribing clinician based on the patient’s medical condition, severity of symptoms, renal and hepatic function, and concomitant therapies. No fixed regimen is provided here; the healthcare professional will set the appropriate strength and frequency.

Safety data for Meldonium in pregnancy and lactation are limited. Current guidance recommends avoiding its use unless the potential therapeutic benefit clearly outweighs any possible risk to the fetus or infant. Physicians should discuss individual risk factors with patients before initiating therapy.

To request Mildronate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Meldonium differs from traditional anti‑ischemic agents such as nitrates or beta‑blockers by targeting cellular metabolism rather than vascular tone. It reduces reliance on fatty‑acid oxidation, which can improve oxygen efficiency without causing significant blood pressure changes. However, clinical choice depends on patient profile, comorbidities and physician experience.

Mildronate tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain potency.

Mildronate is supplied as an oral tablet taken by mouth with water. The prescribing physician determines the exact dosing schedule, which may be once or multiple times daily, based on the individual’s clinical condition and response to therapy.

Serious adverse events, although rare, include severe allergic reactions (such as rash, angioedema, or Stevens‑Johnson syndrome), significant hypotension, and cardiac arrhythmias. Patients should be monitored for any sudden changes in blood pressure, heart rhythm, or signs of hypersensitivity, and medical attention should be sought promptly if they occur.

Meldonium is contraindicated in individuals with known hypersensitivity to the drug or its excipients. Caution is advised for patients with uncontrolled hypertension, severe cardiac arrhythmias, or those who are pregnant or breastfeeding unless the therapeutic benefit justifies potential risks.